Ignite Creation Date:
2024-05-06 @ 8:04 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06247748
Status:
COMPLETED
Last Update Posted:
2024-02-08
First Post:
2024-01-22
Brief Title:
Influence of JY09 on Pharmacokinetics of Metformin Rosuvastatin and Digoxin and the QT Interval Study in Overweight Chinese Subjects
Sponsor:
Beijing Dongfang Biotech Co Ltd
Organization:
Beijing Dongfang Biotech Co Ltd
Study Overview
Official Title:
Evaluation of the Effects of Exendin-4 Fc Fusion Protein JY09 Injection on the Pharmacokinetic Profiles of Metformin Hydrochloride Tablets Rosuvastatin Calcium Tablets and Digoxin Tablets and on the QT Interval in Overweight Chinese Subjects
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is conducted in china The aim of the trial is as follows
To assess the effect of multiple subcutaneous injections of JY09 injection on the pharmacokinetic PK profile of multiple oral doses of metformin hydrochloride tablets a single oral dose of Rosuvastatin calcium tablets or digoxin tablets in overweight Chinese subjects
To assess the effect of multiple subcutaneous injections of JY09 injection on QT interval in overweight Chinese subjects
To assess the effect of multiple subcutaneous injections of JY09 injection on the pharmacokinetic PK profile of multiple oral doses of metformin hydrochloride tablets a single oral dose of Rosuvastatin calcium tablets or digoxin tablets in overweight Chinese subjects
To assess the effect of multiple subcutaneous injections of JY09 injection on QT interval in overweight Chinese subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None